Aclaris Therapeutics ACRS Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The official record: Aclaris Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
- Aclaris Therapeutics (ACRS) reported business combination contingent consideration arrangements change in amount of contingent consideration liability1 of $400K in Q4 2025.
- What is the long-term trend for Aclaris Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1?
- Over 3 years (2021 to 2025), Aclaris Therapeutics's business combination contingent consideration arrangements change in amount of contingent consideration liability1 has grown at a -54.5% compound annual growth rate (CAGR), from $24.34M to $2.3M.
- What does business combination contingent consideration arrangements change in amount of contingent consideration liability1 mean?
- Reflects the periodic adjustments to the fair value of liabilities related to earn-outs or milestone payments from past acquisitions. Changes in this amount indicate shifts in the probability or timing of achieving specific clinical or commercial milestones tied to acquired assets. This metric provides insight into the financial impact of historical M&A activity and potential future cash outflows.